Skip to content

English

繁體中文

syneuRx-logo
  • About
    • Mission
    • Leadership Team
    • Major Milestone
    • Contact
  • Service
    • New Drug Development
  • Research
    • Antiviral Platform
    • NMDA Platform
    • Pipeline
  • Trials
    • SNA11
    • SNG12
    • SND12
  • PRODUCT
  • Newsroom
    • Press Release
    • Publication
    • Media
  • About
    • Mission
    • Leadership Team
    • Major Milestone
    • Contact
  • Service
    • New Drug Development
  • Research
    • Antiviral Platform
    • NMDA Platform
    • Pipeline
  • Trials
    • SNA11
    • SNG12
    • SND12
  • PRODUCT
  • Newsroom
    • Press Release
    • Publication
    • Media

Press Release

ALL

2022

2021

2020~2015

Sep 10, 2018

SyneuRx’s SNS Patent Applications Have Been Granted in Taiwan and in the US.

May 22, 2017

First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia

May 11, 2017

First Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trial

Apr 04, 2016

FDA Approves SyneuRx’ IND Application for Late Phase Clinical Development of a Mild Dementia Treatment

Dec 19, 2015

SyneuRx Receives US FDA Breakthrough Therapy Designation for SND12 for the Treatment of Refractory Schizophrenia in Adults

Privacy Policy

Terms of Use

Contact

About

  • Mission
  • Leadership Team
  • Major Milestone

Research

  • Antiviral Platform
  • NMDA Platform
  • Pipeline

Trials

  • SNA11
  • SNG12
  • SND12

Newsroom

  • Press Release
  • Publication
  • Media
SyneuRx International (Taiwan) Corp.
Copyrights © 2013 SyneuRx Corp. All rights reserved.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.okPrivacy policy